Current and Emerging Treatments for the Management of Ocular Surface Disease: Targeting Mites and More (CME/CE Webcast)
Activity Description and Purpose
This educational activity introduces clinicians to advanced diagnostics and management strategies for ocular surface disease. Through case presentations and discussions, the program delves into the latest clinical data and treatment methodologies, including the use of targeted therapies for Demodex blepharitis. Participants will engage in a comprehensive review of ocular surface disease, from identifying key signs and symptoms to exploring effective treatment plans. The desired results of this educational activity are for clinicians to implement best practices in the diagnosis of patients with blepharitis, gain confidence in developing individualized treatment plans for patients with blepharitis, and review relevant clinical data on emerging treatments for blepharitis.
This educational activity is intended for ophthalmologists and optometrists.
After completing this activity, participants will be better able to:
- Implement best practices in the diagnosis of blepharitis
- Review relevant clinical data on treatments for blepharitis
- Develop individualized treatment plans for patients with blepharitis
Kenneth A. Beckman, MD, FACS (Chair)
Deepinder K. Dhaliwal, MD, LAc
|Darrell White, MD
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Kenneth A. Beckman, MD, is a consultant for Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Bio-Tissue, Bruder Healthcare, Dompé US, Inc, EyePoint Pharmaceuticals*, Glaukos Corporation, Glint Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Inc*, Novaliq GmbH, Novartis Pharmaceuticals Corporation*, Ocular Science, Ocular Therapeutix, Inc*, Shenyang Sinqi Pharmaceutical Co, Ltd, Sun Pharmaceutical Industries, Inc, TearLab Corporation, Thea Pharmaceuticals Limited, Verséa Health, Inc, Visus Therapeutics, Yuyu Pharma, Inc, and Zeiss; is a contracted researcher for Aerie Pharmaceuticals, Inc, and Glaukos Corporation; and owns stocks or stock options in RxSIGHT.
Deepinder K. Dhaliwal, MD, LAc, is a consultant for Haag-Streit Group, Oyster Point Pharma, Inc, and Tarsus Pharmaceuticals, Inc; is an advisory board member of Bausch & Lomb Incorporated, CSI Dry Eye, EyeYon Medical, Lenz Therapeutics, STAAR Surgical, TearSolutions, and Trefoil Therapeutics, LLC; and is a contracted researcher for Amber Ophthalmics, Bausch & Lomb Incorporated, Epion Health, Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, and KOWA Pharmaceuticals America, Inc.
Darrell White, MD, is a consultant for Aldeyra Therapeutics, Allergan, Bausch & Lomb Incorporated, Bruder Healthcare, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Santen Inc, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Trukera, and Viatris Inc; is on the speakers bureau for Allergan, Bausch & Lomb Incorporated, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Viatris Inc; and has stock options that have not been exercised in Oyster Point Pharma, Inc.
* The financial relationship existed during the past 24 months but has now ended.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 89144-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
This activity, COPE Activity Number 127543, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Tarsus Pharmaceuticals, Inc, and Théa Pharma Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Tarsus Pharmaceuticals, Inc, or Théa Pharma Inc.
©2024 MedEdicus LLC. 306b
- 1.00 AMA PRA Category 1 Credit™
- 1.00 COPE
- 1.00 Participation